Patient baseline characteristics
| . | Number (N = 15) . | Percentage (%) . |
|---|---|---|
| Age at transplant (y), median (range) | 9.1 (0.3-21.4) | |
| Sex | ||
| Male | 11 | 73% |
| Female | 4 | 27% |
| Race | ||
| White | 8 | 53% |
| Black | 2 | 13% |
| Asian/Pacific Islander | 1 | 7% |
| Other | 3 | 20% |
| Not disclosed | 1 | 7% |
| Ethnicity | ||
| Non-Hispanic/Latino | 8 | 53% |
| Hispanic/Latino | 4 | 27% |
| Not disclosed | 3 | 20% |
| Diagnosis | ||
| Nonmalignant | 8 | 53% |
| Malignant | 7 | 47% |
| Conditioning | ||
| MAC | 10 | 67% |
| RIC | 3 | 20% |
| None | 1 | 7% |
| Unknown∗ | 1 | 7% |
| HLA type (A, B, C, DRB1) | ||
| Matched unrelated | 5 | 33% |
| Matched related | 3 | 20% |
| Mismatched unrelated | 6 | 40% |
| Haploidentical | 1 | 7% |
| Cell source | ||
| Bone marrow | 13 | 87% |
| Peripheral blood | 1 | 7% |
| Unknown∗ | 1 | 7% |
| PrioraGVHD | ||
| Yes | 9 | 60% |
| No | 5 | 33% |
| Unknown∗ | 1 | 7% |
| Time to cGVHD from HCT (d), median (range) | 168 (100-420) | |
| Time to LD IL-2 from cGVHD diagnosis (d), median (range) | 234 (11-542) | |
| Age at LD IL-2 start (y), median (range) | 10.4 (1.2-23.2) | |
| Time on LD IL-2 (d), median (range) | 462 (8-1489) | |
| . | Number (N = 15) . | Percentage (%) . |
|---|---|---|
| Age at transplant (y), median (range) | 9.1 (0.3-21.4) | |
| Sex | ||
| Male | 11 | 73% |
| Female | 4 | 27% |
| Race | ||
| White | 8 | 53% |
| Black | 2 | 13% |
| Asian/Pacific Islander | 1 | 7% |
| Other | 3 | 20% |
| Not disclosed | 1 | 7% |
| Ethnicity | ||
| Non-Hispanic/Latino | 8 | 53% |
| Hispanic/Latino | 4 | 27% |
| Not disclosed | 3 | 20% |
| Diagnosis | ||
| Nonmalignant | 8 | 53% |
| Malignant | 7 | 47% |
| Conditioning | ||
| MAC | 10 | 67% |
| RIC | 3 | 20% |
| None | 1 | 7% |
| Unknown∗ | 1 | 7% |
| HLA type (A, B, C, DRB1) | ||
| Matched unrelated | 5 | 33% |
| Matched related | 3 | 20% |
| Mismatched unrelated | 6 | 40% |
| Haploidentical | 1 | 7% |
| Cell source | ||
| Bone marrow | 13 | 87% |
| Peripheral blood | 1 | 7% |
| Unknown∗ | 1 | 7% |
| PrioraGVHD | ||
| Yes | 9 | 60% |
| No | 5 | 33% |
| Unknown∗ | 1 | 7% |
| Time to cGVHD from HCT (d), median (range) | 168 (100-420) | |
| Time to LD IL-2 from cGVHD diagnosis (d), median (range) | 234 (11-542) | |
| Age at LD IL-2 start (y), median (range) | 10.4 (1.2-23.2) | |
| Time on LD IL-2 (d), median (range) | 462 (8-1489) | |
aGVHD, acute GVHD; MAC, myeloablative conditioning; RIC, reduced intensity conditioning.
One patient had received transplantation elsewhere with few records before her presentation for evaluation of her cGVHD.